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Resistance is a constant challenge for anti-infective drug development. Since they kill sensitive organisms,
anti-infective agents are bound to exert an evolutionary pressure toward the emergence and spread of resistance
mechanisms, if such resistance can arise by stochastic mutation events. New classes of medicines under
development must be designed or selected to stay ahead in this vicious circle of resistance control. This involves
both circumventing existing resistance mechanisms and selecting molecules which are resilient against the
development and spread of resistance. Cell-based screening methods have led to a renaissance of new classes of
anti-malarial medicines, offering us the potential to select and modify molecules based on their resistance potential.
To that end, a standardized in vitro methodology to assess quantitatively these characteristics in Plasmodium
falciparum during the early phases of the drug development process has been developed and is presented here. It
allows the identification of anti-malarial compounds with overt resistance risks and the prioritization of the most
robust ones. The integration of this strategy in later stages of development, registration, and deployment is also
discussed.
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Resistance is a phenomenon common to all anti-
infective agents that can be defined as a genetically
encoded reduction in efficacy of a drug. Anti-malarial
medicines are amongst the most commonly used drugs
worldwide, and historically the supervision of their ad-
ministration has been relatively unsupervised. This com-
bination of factors has led to the successive demise of
first line treatments such as chloroquine, proguanil,
pyrimethamine, sulphadoxine-pyrimethamine and meflo-
quine, which are unable to produce a 90% clinical re-
sponse in many areas where they have been deployed
intensively [1,2]. Some medicines are clearly more prone
to resistance selection than others: resistant strains to
chloroquine took decades to emerge, but those to the
electron transport inhibitor atovaquone were identified
almost in parallel with its first clinical use [3]. This dif-
ference has a clear molecular basis: chloroquine resist-
ance requires several mutations in the transporter pfcrt* Correspondence: dingx@mmv.org
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reproduction in any medium, provided the or(chloroquine resistance transporter), whilst atovaquone
resistance requires a single point mutation in the mito-
chondrially encoded cytochrome bc1 pfcytb (cytochrome
b) [4]. Altogether, the nature of antimalarial compounds,
of their targets, and of the interactions between them ul-
timately determines the genetic ability of Plasmodium
parasites to acquire resistance mechanisms. Whether
these mechanisms will emerge and spread in the wild
further depends on several factors operating at the host
and population levels (Table 1).
Fortunately, development of resistance to artemisinin,
on which are based current first-line therapies for un-
complicated and severe P. falciparum malaria, has been
relatively slow. This is partly due to recommendations
from the World Health Organization (WHO) that only
fixed-dose combinations of artemisinin derivatives with
other anti-malarials should be used. It is also because of
the relative difficulty of generating artemisinin resist-
ance, which has been reassuringly problematic, even in
the laboratory [5]. The first signs of a reduction of the
anti-parasitic activity of artemisinins are emerging, with
a decrease in parasite clearance time being seen in
Cambodia and Thailand, and the first hints of a possibled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Resistance associated factors
Factor Level of action Variables
Drug mode-of-action Parasite Target nature (cellular process, protein, other).
Target gene localization (nuclear or mitochondrial genome).
Drug subcellular localization (vacuole, organelle, cytoplasm).
Resistance mode-of-action Parasite Target mutation rate.
Nature of mutations required for resistance (single nt, in/del, copy number).
Number of mutations required for resistance (causal and compensating).
Fitness Human host Growth rate of resistant parasite (within host competition)
Effect of drug on gametocytogenesis and gametocyte viability.
Effect of resistance mutations on gametocytogenesis and gametocyte viability.
Drug pharmacokinetic Human host Clinical parasite reduction ratio
Drug half-life
Drug dosage
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the spread of resistance can be controlled, there will be
a need for new classes of anti-malarial drugs. This is a
race against time, given that the time taken to develop
new medicines often exceeds a decade. Developing new
medicines that will withstand resistance is a combination
of reducing the possibility that resistant parasites will
arise and preventing their transmission. First, finding
new molecular classes with a low probability that resist-
ance would arise should be a consequence of more hol-
istic cellular based screening, which has the advantage of
potentially selecting for polypharmacology; in other
words molecules that hit more than one target. Fitness
cost is a key factor in this equation as well: if it is not
possible to produce a resistant phenotype with a low fit-
ness cost, then these strains are likely to be replaced by
sensitive strains when the drug pressure is relaxed. Sec-
ond, understanding the role of new inhibitors on trans-
mission is also critical at an early stage, since resistant
parasites which are inefficiently transmitted are a far
lower threat to global public health concern. Anti-folate
resistance had a marked differential effect on transmis-
sion which may have accelerated its spread [9]: clearly a
molecular class with the opposite trend would be prefer-
able. Third, the spread of resistance can be reduced by
combining multiple agents with distinct modes of-
action; since any organism resistant to one component
of the combination should be eliminated by the other.
This raises the barrier for resistance, since the parasite
would have to acquire both resistances simultaneously,
which is far less likely, assuming the mutation eventsare stochastic [10]. The combination of artemether-
lumefantrine has been protected against the emergence
of lumefantrine resistance despite being used to treat over
500 million patients, partly because lumefantrine has
never been used as a monotherapy. Fixed dose combina-
tions prevent sub-optimal monotherapy treatment, and
will restrict the spread of resistance [10,11], provided the
optimal dose ratio can be deployed. Multiple first-line
therapies would also help, but the key is to have medicines
which are as different as possible and current strategies
would only allow use of artemisinin combination therapies
[12,13]. Putting together these three factors in models to
simulate drug resistance emergence in the wild is an im-
portant task, but is still at an early stage [14-16].
The lifespan of the next generation of anti-malarials in
the face of resistance is a critical question in the debate
over malaria elimination and eradication. If through ju-
dicious selection of the right molecules and good prac-
tice, the time interval from introduction to clinically
significant resistance for the next generation of therapy
can be put at the level of artemisinin, or even better, it is
possible that the disease will be eliminated before clin-
ical resistance occurs. This increases the need to have an
early assessment of the risk of developing resistance
associated with each compound and each combination.
This would not be the single decision criterion, but
would be part of the overall framework of deciding
which compounds to prioritize. The Medicines for
Malaria Venture (MMV) is a product development part-
nership with the mission to discover, develop, and facili-
tate delivery of new, effective and affordable anti-malarial
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cines is to have a coherent view on the required properties
of new medicines, a process often referred to as develop-
ing the “target product profile” or TPP. Since one key as-
pect of this product profile has to be minimal
susceptibility to resistance, it is important to have a stan-
dardized framework to quantitatively assess the risk of re-
sistance associated with preclinical anti-malarial
compounds. Such a framework, based on in vitro P. falcip-
arum experiments, has been developed and is presented.
The experimental strategy is discussed together with the
benefits and limitations of such a standard approach and its
implications for clinical development.Resistance assessment strategy
The MMV assessment strategy has been designed to
achieve three goals: (i) identify potential cross-resistance
to other anti-malarial compounds and naturally occur-
ring phenotypic differences, (ii) quantify the risk, or fre-
quency, of de novo resistance selection in vitro and the
associated fitness cost, (iii) characterize the molecular
mode-of-action of resistance, including an understand-
ing of its genetic basis. This work goes on in parallel
with the optimization and selection of candidate mole-
cules. Clearly not all work needs to be done on all mole-
cules in the discovery pipeline, since the sad truth is that
most chemical series do not result in a molecule which
can be tested in humans. The first aspect should be ana-
lysed when a new chemical series is identified, since this
is something that may be optimized by a medicinal
chemistry approach. The second aspect is probably
series dependent, and requires more intensive measure-
ment, and should wait until a project is at the lead
optimization stage. The final steps should be carried out
in parallel to the clinical candidate selection, since they
are relatively labour intensive. Two test cascades have
been defined to achieve the first two goals systematically,
the results of which can be exploited to the third one
(Figure 1).Goal I: cross-resistance
One of the hallmarks of genetically determined drug-
resistance is a shift in the 50% inhibitory concentration
(IC50) compared to sensitive strains. The first step is
establishing that a new compound is fully active on
known multi-drug resistant (MDR) P. falciparum strains
by measuring its IC50, which is a more robust and repro-
ducible measure than IC90 or IC99. Known anti-malarial
resistance is principally determined by only a handful of
genes (Figure 2). These include specific molecular tar-
gets, such as those for antifolates pfdhps (dihydroptero-
ate synthase) and pfdhfr (dihydrofolate reductase) and
electron transport inhibitors pfcytb (cytochrome bc1). Inaddition there are transporters such as pfcrt (chloro-
quine) and pfmdr1 (multidrug resistance 1).
A collection of resistant strains has been selected to
cover at least all the naturally occurring and genetically
defined known resistance mechanisms (Table 2). In this
context, we will define resistance as IC50 value 20-fold
higher than that of the reference IC50 value from a pan-
sensitive P. falciparum strain, typically NF54. This
threshold gives room for intrinsic IC50 variations in the
growth rate or other biological or experimental para-
meters not directly related to resistance mechanisms
[17]. The strains selected cover the majority of known
genetic variations. The chloroquine transporter pfcrt
mutation K76T is associated with additional mutations
(CVIET and SVMNT alleles which are found in the FCB
and 7G8 strains). The V1/S strain has mutations in
pfdhfr leading to four amino acid substitutions showing
high levels of resistance to cycloguanil and pyrimeth-
amine [18]. HB3 is resistant to pyrimethamine but not
cycloguanil, while FCB shows the contrary pattern [18].
Dd2 and FCB show increased copy numbers of pfmdr1,
and mutations at several codons. These changes influ-
ence sensitivity to multiple drugs, including mefloquine
and artemisinin derivatives [5,19]. NF54 and 7G8 have a
20-fold shift in IC50 to sulphadoxine, as a result of muta-
tions in pfdhps whilst Dd2 has a high level resistance,
when tested in a low para-aminobenzoic acid (pABA)
medium [20,21]. TM90C2B is resistant to atovaquone,
due to a mutation in pfcytb [22]. Finally the set also
includes the D6 strain, which shows, in some studies, a
low level of natural resistance to mefloquine [23]. The
K1 strain recapitulates most of the natural resistance
mechanisms described above and therefore is a good
first filter that can be performed early in the screening
process. Clearly over the next few years it will be import-
ant to add new resistance mechanisms. For example, re-
sistance to the new spiroindolone NITD609 (in Phase
IIa) is linked to pfatp4 as a potential resistance mechan-
ism [24], demonstrating that new classes of compounds
can bring new resistance mechanisms.
Since these MDR strains were adapted to culture and
cloned many years ago, and have been passaged since
that time, they may not represent the wild-type field
Plasmodium parasites. Moreover, only P. falciparum can
be stably cultured in the laboratory. It is therefore essen-
tial to test compounds against contemporary field
isolates of all the human-infecting species, including
Plasmodium vivax, Plasmodium ovale and Plasmodium
malariae. This gives good background information on
variability, and allows confirmation that the compound
is active on all species. The analysis of at least 10
P. falciparum and 10 P. vivax isolates appears a minimal
requirement, if a 20-fold change in IC50 is used as a
cut-off [42].
Figure 1 Resistance risk assessment workflow. The resistance risk assessment workflow encompasses three goals: cross-resistance
determination (goal I), de novo resistance selection frequency determination (goal II), and resistance mode-of-action determination (goal III). These
can be achieved trough a straightforward set of quantitative experiments applied to compounds at the lead and preclinical developmental
stages. A resistant IC50 corresponds to a 20-fold increase as compared to a fully sensitive strain (NF54 or HB3 in the case of sulphonamides). C is
the theoretical cost of fitness associated with resistance (see main text). C<0 indicates that resistance provides a fitness advantage, which is a
major risk factor. Ultimately, the overall risk level can be classified as low, elevated, or major and allows to prioritize the development of robust
compounds and to establish risk mitigation strategies for the others.
Figure 2 Known genetic determinants of naturally occurring resistance mechanisms. Mutations (red dot) of the dihydrofolate reductase
(PfDHFR) enzyme prevent its inhibition by the antifolate drugs pyrimethamine (PYR) and cycloguanil (CYC). Similarly, sulphadoxine (SDX)
resistance is mediated by mutations of its target dihydropteroate synthetase (PfDHPS). Atovaquone (ATO) binds to the cytochrome bc1 complex
(PfCYTB), mutations of which have been shown to induce high level of ATO resistance. Chloroquine (CHQ) is believed to prevent haeme
detoxification within the digestive vacuole. Mutations of the CHQ resistance transporter (PfCRT) as well as of the multidrug resistance protein-1
(PfMDR1), including copy number variations, have been shown to compromise CHQ action by preventing its accumulation within the digestive
vacuole. Mutations of these two transporters have also been implicated with mefloquine resistance, although definite marker has not been
established for this drug.
Ding et al. Malaria Journal 2012, 11:292 Page 4 of 11
http://www.malariajournal.com/content/11/1/292
Table 2 Panel of multidrug resistant strains including specifc amino acid changes
drug resistancea pfcrtb pfmdr1c pfdhfrd pfdhpse pfcytb
Strain CHQ SUL PYR CYC MEF ATO 72 73 74 75 76 86 184 1034 1042 1246 copy 16 51 59 108 164 436 437 581 613 268 Origin MR4
number
Ref.
NF54 S S S S S S C V M N K N Y S N D 1 A N C S I S G A A Y Imported MRA-100 [25]

















V1/S R R R R C V I E T Y Y S N D A I R N L F G A T Cloned from
V1 (Vietnam)
MRA-176 [30]
K1 R R R R C V I E T Y Y S N D 1 A N R N I S G G A Thailand MRA-159 [31]
FCB R S R C V I E T Y Y S N D 2 V N C T I Columbia MRA-309 [32]
TM90C2B R R R R C V I E T N F S N D S Thailand N/A [3]
aS: sensitive, R: resistant, as reported in the literature.
bAllelic information based on references [33-35].
cAllelic information based on references [33,35-37].
dAllelic information based on references [18,35,38].
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Resistant parasites can be selected by applying drug
pressure in vitro and in vivo [22]. These approaches have
successfully identified genes, and sometimes codons
involved in naturally occurring resistance [22]. The sin-
gle nucleotide changes behind these mutations are
estimated to occur at a rate of approximately 10-9 per
nucleotide site per replication, similar to other eukar-
yotes [43-45]. Changes in sensitivity are also caused by
gene copy number variations, which occur as often as
10-4 per nucleotide site per replication [45,46].
The simplest approach is in vitro selection of resistant
parasites, which can be applied on a large number of com-
pounds earlier in drug discovery. P. falciparum intraery-
throcytic cultures, with starting inocula ranging from 105
to 109 parasites, are exposed to a concentration of the
compound nearing IC90 and monitored during 60 days for
recrudescent parasites (Figure 3a). The minimal inoculum
for resistance (MIR) can be determined and is an indirect
measure of the likelihood of a resistant genotype to occur
and to be selected in vitro. In addition, the IC50 shift of
the resistant mutants as compared to the parental sensi-
tive strain is a measure of the resistance intensity [47-49].
Dd2 has an accelerated resistance to multiple drugs
(ARMD) phenotype, possibly due to defective DNA repair
mechanisms [47,50], and is therefore an ideal strain to in-
vestigate rare mutational events within the practical limits
of in vitro culture volumes. Importantly, MIR from
ARMD strains are assumed to be lower because of the
general higher mutation rate of these parasites and not be-
cause they acquire alternative resistance mechanisms.
Moreover, ex vivo results seem to be in good agreement
with clinical experience. Atovaquone resistance is gener-
ated relatively easily in patients, and in laboratory experi-
ments results either in low MIR or large IC50 increases
[3,4,47]. Chloroquine and artemisinin derivatives, which
escaped resistance clinically for a long time despite wide-
spread use as monotherapy, do not readily produce stable
resistant mutants in selection experiments [22].
A combination of MIR and IC50 increase in Dd2 can be
used to flag compounds at high risk of resistance
(Figure 3b). An MIR equal to or below 105 is a major risk,
as it suggests that only a single nucleotide mutation is suf-
ficient. A MIR of 107 would also be high risk, if combined
with a greater than 20-fold shift in the IC50. Combinations
of MIR and IC50 shift data available in the literature are
presented in the Figure 3b and Table 3. This limited data
set shows strain dependence of MIRs, atovaquone show-
ing an MIR of 105 for in W2 and at 6×108 in K1 [4,47].
For example, the confirmation that cyclopropyl carboxa-
mides had an MIR of less than 108 in the standard 3D7
strain, and an IC50 shift of 100-fold range, gives two clear
signals that the series should be put on hold, unless other
redeeming features can be identified [51].Mutations that give a selective advantage against drugs
often cause a reduction in fitness in its absence [53,54].
A key fitness parameter is the relative asexual growth
rate [55], measured in vitro by monitoring cultures
seeded with the derived resistant and the original (sensi-
tive) parental strain at a given ratio. The evolution of the
strain ratio can then be monitored by DNA sequencing
or qPCR [56-58]. The proportional loss of fitness (C)
can be calculated from the change in strain ratio ΔRn,
after n generations, where that value is equal to 1/(1-C)n
[58]. If C ≥ 0 the sensitive strain will outgrow the resist-
ant strain, however, if C<0 this would be major potential
risk, suggesting that the strain may also out-compete the
original wild type in humans. Of note, such a scenario
has already been observed with P. chabaudi chloroquine
and pyrimethamine resistant parasites displaying a fit-
ness gain even in the absence of drug pressure [53]. A
second key parameter of parasite fitness is its transmis-
sion potential, which depends not only on its growth
rate but also on its ability to produce viable gametocytes.
The effect of resistance can also be investigated on the
sexual phase of the parasite cycle, using recently devel-
oped in vitro methods [59]. A resistant parasite unable
to complete a sexual cycle is of no clinical relevance, as
it cannot be transmitted.
In vivo resistance selection experiments allow a more
physiological variation of the drug concentration and are
more representative of the clinical situation [60]. For in-
stance, the pfcytb Y268C mutation conferring atova-
quone resistance in the wild could only be reproduced
using a rodent in vivo model [61]. However, in vivo
experiments do not allow to control the level of drug
pressure or the number of parasite subjected to it and
are not ideal to profile and cross-compare a large num-
ber of early compounds.
Goal III: understanding the molecular mechanism
of resistance
One key to understanding the importance of a resistant
phenotype is its molecular characterization. Mutations
in genes encoding pumps and transporters are concern-
ing, since they could imply parallel resistance generation
to a wide variety of different molecules. Point mutations
may enable a link with the molecular target to be estab-
lished. The genetic changes causing resistance can be
identified using tiling arrays, full genome sequencing or
linkage analysis and candidate genes can be validated
using allelic exchange experiments [62-65]. The full
genome sequences of a large number of P. falciparum
parasites from diverse locations have already been deter-
mined [66]. For those molecules like NITD609 for which
molecular markers of resistance have already been
identified, it will also be important to examine these
sequences and determine whether the target gene is
Figure 3 In vitro resistance selection assessment. (a) A standard in vitro protocol for resistance selection frequency measurement uses defined
starting inocula of a P. falciparum strain pressured with a constant level of drug nearing the IC90. Parasitemia falls below detection limits but
eventual resistant parasites are able to recrudesce and to be cloned for subsequent determination of the IC50 fold increase. The minimal
inoculum for resistance (MIR) is a measure of the resistance selection frequency, while the IC50 fold increase measures the level of resistance. (b)
These two endpoints are used to classify anti-malarial compounds according to risk levels (see main text). It is advisable to run control
experiments in parallel with compounds known to select resistance readily, such as atovaquone.
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straightforward examination will give advance warning
of any regions where resistant parasites might already by
present, and easily selected by use of the drug.Table 3 MIR and associated IC50 fold increase reported in the
Compound Strain Pressure MIR IC
Atovaquone W2 10×IC50 1×10
5 3
Atovaquone K1 6×/16×IC50 6×10
8 9
Piperaquine Dd2 2×IC50 8.5×10
8 1
Chloroquine 106/1 3×IC50 6×10
8 1
GSK2645947 3D7 10×IC50 <10
8 1
an/a:non available.Additionally, in vitro experiments performed to cha-
racterize the compound speed of action and its activity
at various stages of the parasite lifecycle can be repeated
using resistant parasites in order to better understandliterature
50 fold increase Mechanism
a Ref.a
0x n/a [47]
00x single point mutations in pfcytb [4]
00x 63-kb fragment amplification [49]
00x single point mutations in pfcrt [52]
00x n/a [51]
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in imaging also allow monitoring the intraerythrocitic
life cycle of the parasites in vitro and in vivo and could
similarly be used to compare resistant and sensitive
parasites [68].
Clinical and regulatory requirement
The development of technologies for assessing resistance
means that comprehensive resistance testing should take
place at all phases of drug development, including post-
marketing pharmacovigilance (Figure 4). Ideally, the preclin-
ical studies will have produced resistant strains and identi-
fied resistance markers, which are especially useful in the
post-marketing surveillance phase. Resistance selection
could also be performed for both partners of potential thera-
peutic combination using single-resistant mutants to evalu-
ate the frequency of double-resistance, which should be
equal or inferior to the single-resistance selection frequency.
The identification of in vitro resistance markers allows care-
ful monitoring for their potential appearance during clinical
trials. Analysis of samples during dose ranging studies for re-
sistance selection could have an impact on dose selection,
but presumably only if the changes in the IC50 value were
relatively minor. Systematic monitoring of resistance selec-
tion in Phase III will consolidate the data on frequency and
help to consolidate the understanding of the development of
resistance in different geographic and endemicity settings.
This will be important information for the regulatory filings,
for national malaria control programmes, and for coordi-
nated efforts of resistance monitoring [69]. Regulators have
universally recognized the importance of a systematic ap-
proach to the characterization of new compounds in regard
to their resistance generation potential. The US-FDAFigure 4 Resistance profiling and clinical development. In vitro selectio
resistance markers can be identified. This permits the identification of more
resistance studies with parasites already resistant to potential partner drugs
include resistance selection as a clinical factor and to insure the appropriat
will also directly benefit from the a priori knowledge of resistance markers.recommend in their ‘Guidance for Industry for Malaria drug
development’ that “the ability of Plasmodium strains to de-
velop resistance when subjected to drug pressure should be
examined in appropriate in vitro and/or in vivo models; this
examination should include evaluating the potential for
cross-resistance to drugs in the same class or in other
classes. If resistance is demonstrated, it is important to iden-
tify the mechanism of resistance. Attempts should be made
to evaluate the clinical significance of any changes in pheno-
type (e.g., in vitro susceptibility to the drug) or genotype
observed in preclinical studies by correlating such changes
with clinical outcome” [70].
Characterization of resistance potential has been men-
tioned in the registration summaries of all anti-malarials
submitted stringent regulatory authorities in the past ten
years: CoartemW (artemether-lumefantrine, Novartis) to
the US-FDA; Eurartesim (dihydroartemisinin-piperaquine,
Sigma-Tau) at the EMA; and more recently Pyramax
(pyronaridine-artesunate, Shin Poong Pharmaceuticals)
which obtained marketing authorization under the EMA’s
article 58) [71-73]. The MMV strategy for resistance
characterization will provide this information for the
regulators and ensure a complete resistance registration
package.
Conclusion
The process presented here integrates information about
the potential importance of resistance selection and
spreading into the preclinical and clinical development
programme for new anti-malarial drugs. At the preclin-
ical level, the experimental framework requires a test
cascade of six essential steps covered by three specific
experimental procedures. The output of this workflown experiments typically generate resistant parasites from which
robust combinations by assessing acquired and de novo cross-
. Resistance markers can be monitored during Phase II and III to
e resistance data package for registration. Post-marketing surveillance
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vated or major (Figure 1 and 3b). This is one of the fac-
tors that will be discussed as part of the preclinical
candidate selection process, a decision matrix which
includes safety margin, and severity of safety signals
observed, human predicted potency, speed of killing, ef-
fect on other lifecycle stages such as gametocytes and
hypnozoites [74]. A major risk suggests that the com-
pound will either face pre-existing resistance or will se-
lect new clinically significant mechanisms of resistance.
This risk level should prevent further development of
the compound, in the absence of a clear mitigating fac-
tor linked to major synergy in combination studies. An
elevated risk is associated where there is a clear signal,
and is an obvious concern. Provided that there are a
small number of other elevated risks in the candidate se-
lection matrix these compounds can be progressed, but
resistance needs to be continually monitored in clinical
studies, and will be a key factor in the selection of dose
and combination partner. Risk mitigation is essential,
making it important to understand the molecular mech-
anism, and to have genetic markers to survey its occur-
rence. A low risk classification suggests that resistance is
unlikely to arise, although it is still important to continu-
ally monitor for changes in IC50 in the clinical program.
The outcome of resistance studies has several implica-
tions influencing decision making in drug development.
First, the IC50 as part of the calculation for the predic-
tion of human dose should include the range of poten-
cies observed, and focus on the value from the most
resistant parasites. This needs to be continually re-
evaluated based on emerging data from primary field
isolates. Second, potential cross-resistance amongst part-
ners in drug combinations can be checked using labora-
tory derived resistant strains. Ideal drug combinations
are these that regroup compounds driving opposed or
even incompatible resistance mechanisms [75]. Third,
the knowledge of in vitro identified mutations conferring
resistance and susceptible genes allow monitoring during
the large scale clinical trials in Phase III and post-launch,
to give an early warning signal for the emergence of clin-
ically significant effects.
The experimental strategy presented here also has limita-
tions. It applies to compounds acting against P. falciparum
asexual intraerythrocytic stage only. However, these repre-
sent the majority of the parasite biomass. Although the next
generation of anti-malarials may include increased focus on
the hepatic forms, understanding potential resistance selec-
tion at these lifecycle stages will be supported by knowledge
of the resistance mechanisms in intraerythrocytic stages.
Another limitation is the standardized approach itself.
Resistance is a complex phenomenon that will require
tailor-made studies. For instance, artemisinin resistance as
currently observed does not translate into clear IC50 shift,rendering its study in cross-resistance and resistance selec-
tion experiments challenging [5]. However a standardized
method does at least allow a common framework for com-
paring compounds and making development decisions.
The workflow presented here allows to measure the
risks of resistance generation, the magnitude of the
change in IC50, and the effect on transmission at an
early stage in drug discovery. By determining the mo-
lecular mechanism of resistance, and identifying poten-
tial cross-resistance issues, high-risk chemical series can
be de-prioritized, in a time and cost effective manner.
The generation of a standard resistance profile of new
drugs will supply common information to regulators and
national control bodies to facilitate decision-making.
This information will also allow for the focused monitor-
ing of compounds after registration. This strategy will
contribute to developing long-lasting anti-malarial drugs
by identifying and monitoring robust compounds during
their development.
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